Syed A. Hussain, MD, on Muscle-Invasive Bladder Cancer: NEO-BLADE Trial of Nintedanib Plus Chemotherapy
2020 Genitourinary Cancers Symposium
Syed A. Hussain, MD, of the University of Sheffield, discusses phase II findings comparing nintedanib or placebo in combination with gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer. The data showed that adding nintedanib was safe and well tolerated, with a significant improvement in progression-free and overall survival at 1 and 2 years (Abstract 438).
The ASCO Post Staff
Thomas Powles, MD, PhD, of Queen Mary University of London, summarizes two papers on metastatic renal cell carcinoma for which he was the discussant: nivolumab in combination with stereotactic body radiotherapy in pretreated patients, and combining dual immune checkpoint inhibition with stereotactic radiation (Abstracts 613 & 614).
The ASCO Post Staff
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses findings from a phase I/II trial that found MK-6482 was well tolerated and demonstrated activity in heavily pretreated patients with clear cell renal cell carcinoma (Abstract 611).
The ASCO Post Staff
Julie N. Graff, MD, of Oregon Health & Science University and Knight Cancer Institute, discusses study findings that show pembrolizumab plus enzalutamide after progression on enzalutamide produced clinical activity and can lead to durable responses, with a manageable safety profile. The phase III KEYNOTE-641 trial will test patients who are enzalutamide-naive (Abstract 15).
The ASCO Post Staff
Nicholas D. James, PhD, MBBS, of The Institute of Cancer Research in London, discusses the health economics of adding abiraterone to first-line, long-term hormone therapy in prostate cancer, and what it means for long-term survival, quality-adjusted survival, and cost-effectiveness (Abstract 204).
The ASCO Post Staff
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, describes a currently recruiting phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab vs nivolumab/ipilimumab for patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk (Abstract TPS767).
